Key result
Zhenzhu Tiaozhi capsule matches standard therapy for 2-year lipid-lowering effectiveness in dyslipidemia.
Why the study?
The lipid profile and dynamic trajectories over 2 years in patients with hyperlipidemia receiving Zhenzhu Tiaozhi capsule versus general lipid-lowering treatment in real-world clinical settings were not described.
Does Zhenzhu Tiaozhi (FTZ) capsule improve 2-year lipid profile trajectories compared with general lipid-lowering therapy (statins, fibrates, or Xuezhikang) in adults with hyperlipidemia?
Cohort (n=839)
No
Does Zhenzhu Tiaozhi (FTZ) capsule improve 2-year lipid profile trajectories compared with general lipid-lowering therapy (statins, fibrates, or Xuezhikang) in adults with hyperlipidemia?
This real-world retrospective cohort study suggests that the traditional Chinese medicine Zhenzhu Tiaozhi (FTZ) capsule achieves steady 2-year lipid profile improvements comparable to standard lipid-lowering drugs without the rebound fluctuations observed after 30 weeks in routine practice.
Answers are grounded in this paper and cite their sources.
Should not yet change hyperlipidemia practice; leaves open need for RCTs to confirm FTZ equivalence.
The objective of this work was to study the lipid profile (LDL, TC, TG, and HDL) over 2 years in patients with hyperlipidemia in a real-world clinical setting and to describe the dynamical trajectory of lipid profile change in response to lipid-lowering treatment (Zhenzhu Tiaozhi capsule (FTZ) vs. general lipid-lowering treatment, i.e., statins, fibrates, and Xuezhikang). We conducted a retrospective study that included people aged ≥18 years with hyperlipidemia that initiated lipid-lowering treatment between January 2010 and December 2020. Demographic, diagnosis, and laboratory data were retrieved from hospital’s electronic medical records, including hospital information system (HIS) and the laboratory information system (LIS). Follow-up trajectories of lipid profile were plotted in a generalized additive mixed model (GAMM) with smooth splines. A total of 839 patients with hyperlipidemia were included. Within 2 years, LDL, TC, and TG descended steadily and gently in the FTZ group (N = 99), while the general lipid-lowering treatment (N = 740) shortly improved LDL, TC, and TG before 11 weeks and was no longer present around 30 weeks. After 30 weeks, the trajectory of LDL, TC, and TG fluctuated up and down. Also, for HDL, a similar trajectory was observed before 40 weeks between 2 groups, but the FTZ group showed an increasing trend after 40 weeks, while a similar trend was not seen in the general lipid-lowering group. In this study, FTZ was shown to have similar long-term effectiveness as an alternative lipid-lowering treatment to the general lipid-lowering treatment. The findings of this study provide observational evidence for further studies of FTZ, but more prospective studies are needed to determine the impacts of FTZ on lipid profile.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2021) conducted a cohort in Hyperlipidemia or dyslipidemia (n=839). Zhenzhu Tiaozhi (FTZ) capsule vs. General lipid-lowering treatment (statins, fibrates, or Xuezhikang) was evaluated on Dynamical trajectory of lipid profile (LDL-C, TC, TG, and HDL-C) over 2 years. Zhenzhu Tiaozhi capsule produced steady 2-year reductions in LDL, TC, and TG and an increase in HDL after 40 weeks, demonstrating similar long-term lipid-lowering effectiveness to standard therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: